Mirum Pharmaceuticals (MIRM) Capital Expenditures (2019 - 2026)

Mirum Pharmaceuticals' Capital Expenditures history runs 8 years deep, the most recent figure standing at $664000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 1519.51% year-over-year to $664000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 54.46% YoY), while the FY2025 annual figure was $954000.0, down 3.93% from the prior year.
• Capital Expenditures was $664000.0 for Q1 2026 at Mirum Pharmaceuticals, up from $600000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $779000.0 in Q2 2024 to a low of $13000.0 in Q1 2024.
• Historically, Capital Expenditures has averaged $214142.9 across 5 years, with a median of $97000.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures soared 7966.67% in 2022, then tumbled 83.83% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $242000.0 in 2022, then tumbled by 71.9% to $68000.0 in 2023, then sank by 70.59% to $20000.0 in 2024, then jumped by 2900.0% to $600000.0 in 2025, then advanced by 10.67% to $664000.0 in 2026.
• The last three Capital Expenditures figures came in at $664000.0 (Q1 2026), $600000.0 (Q4 2025), and $187000.0 (Q3 2025), per Business Quant data.